<DOC>
	<DOCNO>NCT00002968</DOCNO>
	<brief_summary>Randomized phase III trial compare effectiveness surgery without monoclonal antibody therapy treat patient stage II colon cancer . Monoclonal antibody edrecolomab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know whether surgery remove colon cancer effect without monoclonal antibody therapy .</brief_summary>
	<brief_title>Edrecolomab Treating Patients With Stage II Colon Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether adjuvant treatment MoAb 17-1A improve probability overall disease-free survival , increase disease-free interval patient undergone resection Stage II colon cancer . II . To determine whether alteration expression cell cycle relate gene ( thymidylate synthase , p53 , cyclin-dependent kinase inhibitor p21 p27 ) predict risk survival recurrence patient population . III . To determine whether alteration marker metastatic potential-expression DCC measure tumor angiogenesis ( microvascular density vascular endothelial growth factor expression ) -predict risk survival recurrence patient population . IV . To determine whether marker cellular differentiation-sucrase isomaltase-predicts risk survival recurrence patient population . V. To determine whether DNA ploidy cell proliferation prognostic tumor recurrence overall survival Stage II colon cancer . VI . To determine whether interaction among tumor marker identify subset patient significantly alter outcome . VII . To determine whether pathologic feature include tumor grade ; tumor mitotic ( proliferation ) index ; tumor border configuration ; host lymphoid response tumor ; lymphatic vessel , venous vessel perineural invasion predict outcome patient population . OUTLINE : This randomize study . Patients stratify accord degree differentiation ( well vs moderately well vs poor ) , vascular lymphatic invasion ( vs yes ) , preoperative serum CEA ( less 5.0 ng/mL v least 5.0 ng/mL v unknown ) . Patients randomize 1 2 treatment arm . Arm I : Patients receive adjuvant edrecolomab IV 2 hour day 1 . Treatment repeat every 28 day 5 course . Patients must begin therapy earlier 7 day later 42 day post-surgical resection . Patients also undergo observation 3 6 month post-randomization . Arm II : Patients undergo observation 3 6 month post-randomization . Patients follow last course edrecolomab ( arm I ) 12 month ( arm II ) . All patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pathologic documentation adenocarcinoma colon without penetration serosa lymph node metastasis ( Stage II pT3N0 pT4bNO lesion , exclude pT4aN0 ; Modified AstlerColler Stage B2 ) ; distant metastasis penetration adjacent organ structure ; proximal , distal , radial margin must free tumor Important note : A tumor nodule &gt; 3 mm diameter perirectal pericolonic adipose tissue without histologic evidence residual node nodule classify regional/pericolonic node metastasis ; however , tumor nodule = &lt; 3 mm diameter classify T category discontinuous extension ( i.e. , pT3 ) ; multiple metastatic focus see microscopically pericolonic fat consider metastasis single lymph node classification ; although six node evaluate specimen optimal , minimum three node ( periodic mesenteric ) evaluation require inclusion study Complete , en bloc resection primary tumor , perform open procedure , laparoscopically laparoscopically assist No evidence perforation clinical obstruction bowel The gross distal margin primary tumor must lie peritoneal reflection ( i.e. , must colon , rectal cancer ) No previous radiation chemotherapy malignancy CALGB Performance status 01 No concurrent treatment systemic steroid allow ; patient receive replacement steroid adrenal insufficiency eligible ; patient receive inhaled steroid daily dose 500mg less patient treat topical steroid eligible No prior exposure murine antibody ( e.g. , diagnostic test like `` oncoscint scan '' ) No uncontrolled severe cardiovascular disease No history pancreatitis Nonpregnant nonlactating ; patient childbearing potential agree use effective method birth control No previous concurrent malignancy allow , except inactive nonmelanoma skin cancer , situ carcinoma cervix , cancer patient diseasefree &gt; = 5 year ; patient one synchronous primary colon tumor eligible ; purpose protocol , stag classification base stage advance primary tumor Granulocytes &gt; 1,800/μl Platelet count &gt; 100,000/μl BUN &lt; 1.5 x normal Creatinine &lt; 1.5 x normal Bilirubin &lt; 1.5 x normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>